Chemotherapy

MediWound Announces Initiation of U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma

Retrieved on: 
Monday, July 26, 2021
Medicine, Cancer, Melanoma, Clinical medicine, Health, Skin cancer, Chemotherapy, Sulfonamides, MEK inhibitor, Wolfram Samlowski

YAVNE, Israel, July 26, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for tissue repair and regeneration, today announced initiation of its phase I/II study of MW005 for the treatment of low-risk Basal Cell Carcinoma (BCC). In parallel, an investigator-initiated phase II trial of MW005 in non-melanoma skin cancers is being conducted at the Soroka Medical Center in Israel. MediWound expects that data from both studies will be available by the end of 2021.

Key Points: 
  • In parallel, an investigator-initiated phase II trial of MW005 in non-melanoma skin cancers is being conducted at the Soroka Medical Center in Israel.
  • We are excited to initiate this U.S. phase I/II study of MW005, which is the first step in this important clinical development program.
  • MW005, a topical biological drug for the treatment of non-melanoma skin cancers, is a clinical-stage product candidate under development.
  • MW005, our topical biological drug for the treatment of non-melanoma skin cancers, is a clinical-stage product candidate under development.

Fidia announces the FDA Orphan Drug designation for ONCOFID®-P for the treatment of malignant mesothelioma, the cancer caused by exposure to asbestos

Retrieved on: 
Monday, July 26, 2021
Cancer, Clinical medicine, Health, Infectious causes of cancer, Taxanes, Cancer treatments, Antineoplastic drugs, Mesothelioma, Paclitaxel, Bladder cancer, Chemotherapy

The loco-regional administration makes ONCOFID-P an ideal anticancer drug in combination with existing treatments for patients with malignant mesothelioma.

Key Points: 
  • The loco-regional administration makes ONCOFID-P an ideal anticancer drug in combination with existing treatments for patients with malignant mesothelioma.
  • ONCOFID-P is an anticancer drug in advanced clinical development for the loco-regional treatment of non-muscle invasive bladder cancer, on which it has already demonstrated potent efficacy and excellent tolerability.
  • The onset of mesothelioma is closely related to exposure to asbestos, used as an insulator in many industries, from constructions to naval-aircraft and heavy industries.
  • ONCOFID-P is an innovative anti-cancer drug, a conjugate of paclitaxel (taxol) with hyaluronic acid (HA), resulting from the research of Fidia Farmaceutici.

LIXTE BIOTECHNOLOGY COMMENTS ON REPORT THAT ITS PP2A INHIBITOR LB-100 COMBINED WITH ANOTHER INVESTIGATIONAL AGENT STIMULATES BONE GROWTH IN MODELS OF DWARFISM

Retrieved on: 
Thursday, July 22, 2021
Cancer, Clinical medicine, Medicine, Antineoplastic drugs, Cancer immunotherapy, Oncology, Immunotherapy, Chemotherapy

LB-100 has been shown to enhance anti-cancer activity of standard chemotherapy and immunotherapy regimens against a broad spectrum of human cancers in animal models.

Key Points: 
  • LB-100 has been shown to enhance anti-cancer activity of standard chemotherapy and immunotherapy regimens against a broad spectrum of human cancers in animal models.
  • Our focus is to demonstrate the clinical therapeutic benefit of LB-100 in one or more cancers for which more effective treatments are urgently needed.
  • A major driver of cancer is defects in the switches that turn the biochemical pathways in cells on and off.
  • This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at sec.gov/edgar.shtml .

The Silver Nanoparticles Market is projected to surpass $5.5 billion by 2027, says Global Market Insights Inc.

Retrieved on: 
Thursday, July 15, 2021
Chemotherapy, Silver, Silver nanoparticle, Nanoparticle

SELBYVILLE, Del., July 15, 2021 /PRNewswire/ -- Based on a Global Market Insights Inc. report, the global Silver Nanoparticles Market was estimated at $2 billion in 2020 and is slated to exceed $5.5 billion by 2027, registering a CAGR of 14.5% from 2021 to 2027.

Key Points: 
  • SELBYVILLE, Del., July 15, 2021 /PRNewswire/ -- Based on a Global Market Insights Inc. report, the global Silver Nanoparticles Market was estimated at $2 billion in 2020 and is slated to exceed $5.5 billion by 2027, registering a CAGR of 14.5% from 2021 to 2027.
  • The global silver nanoparticles market from healthcare & life science applications should surpass USD 2 billion by 2027.
  • The silver nanoparticles market from textile applications is likely to register over 7.3% gains in the predicted period.
  • The rising spending capacity, evolving lifestyle patterns, and expansion of the fashionable apparel industry should accelerate silver nanoparticles market growth.

GigaGen Publishes Research Describing Novel Mechanism of Action and Therapeutic Potential of its anti-CTLA-4 Drug Candidate, GIGA-564

Retrieved on: 
Wednesday, July 14, 2021
Clinical medicine, Medicine, Branches of biology, T cells, Immune system, Clusters of differentiation, Cancer immunotherapy, Antineoplastic drugs, Checkpoint inhibitor, Regulatory T cell, CTLA-4, Chemotherapy

The publication describes the novel mechanism of action of its anti-CTLA-4 drug candidate, GIGA-564, selected due to its reduced checkpoint inhibition, which resulted in superior anti-tumor activity and lower toxicity in murine models compared to commercially available anti-CTLA-4 drugs.

Key Points: 
  • The publication describes the novel mechanism of action of its anti-CTLA-4 drug candidate, GIGA-564, selected due to its reduced checkpoint inhibition, which resulted in superior anti-tumor activity and lower toxicity in murine models compared to commercially available anti-CTLA-4 drugs.
  • We selected GIGA-564 due to its minimal checkpoint inhibition and its ability to deplete intratumoral Tregs in the tumor.
  • GigaGen is advancing transformative antibody drugs for immune deficiency, infectious diseases and checkpoint resistant cancers by leveraging industry-leading, single-cell technologies.
  • In addition, GigaGens lead oncology asset, GIGA-564, is an anti-CTLA-4 monoclonal antibody that has demonstrated improved anti-tumor efficacy in vivo through a unique mechanism of action.

Society for Immunotherapy of Cancer Publishes Clinical Practice Guideline on Immune Checkpoint Inhibitor-related Adverse Events

Retrieved on: 
Wednesday, July 14, 2021
Clinical medicine, Medicine, Cancer, Immune system, Cancer immunotherapy, Antineoplastic drugs, Checkpoint inhibitor, Immune checkpoint, Chemotherapy, Head and neck cancer, Melanoma, PD-1 and PD-L1 inhibitors

ICIs are treatments that unleash the immune system against cancer, but the same mechanisms that underpin their effective anti-tumor properties may cause unique toxicities, specifically immune-related adverse events (irAEs).

Key Points: 
  • ICIs are treatments that unleash the immune system against cancer, but the same mechanisms that underpin their effective anti-tumor properties may cause unique toxicities, specifically immune-related adverse events (irAEs).
  • "I am pleased to share in the excitement of SITC's long-awaited clinical practice guideline on immune checkpoint inhibitor-related adverse events."
  • SITC has published CPGs for acute leukemia , bladder carcinoma, cutaneous melanoma , head and neck squamous cell carcinoma , immune checkpoint inhibitor-related adverse events , immune effector cell-related adverse events , lymphoma , multiple myeloma, non-small cell lung cancer , prostate cancer and renal cell carcinoma.
  • SITC thanks the American Society of Transplantation and Cellular Therapy (ASTCT) and all participating organizations for providing representatives to serve on SITC's Immune Checkpoint Inhibitor-Related Adverse Events Expert Panel and for their efforts in developing this clinical practice guideline.

Sesen Bio Announces Productive Late-Cycle Meeting with the FDA for Vicineum™

Retrieved on: 
Wednesday, July 14, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Clinical medicine, Medicine, Cancer, Cancer immunotherapy, Immune system, Oncology, Cancer treatments, Antineoplastic drugs, Checkpoint inhibitor, Chemotherapy, Vicineum™, Sesen Bio, VICINEUM™, SESEN BIO

We are very pleased with the outcome of the Late-Cycle Meeting and continue to feel encouraged by the level of engagement from the FDA in our ongoing discussions regarding the BLA for Vicineum, said Dr. Thomas Cannell, president and chief executive officer of Sesen Bio.

Key Points: 
  • We are very pleased with the outcome of the Late-Cycle Meeting and continue to feel encouraged by the level of engagement from the FDA in our ongoing discussions regarding the BLA for Vicineum, said Dr. Thomas Cannell, president and chief executive officer of Sesen Bio.
  • Additionally, Sesen Bio believes that cancer cell-killing properties of Vicineum promote an anti-tumor immune response that may potentially combine well with immuno-oncology drugs, such as checkpoint inhibitors.
  • Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer.
  • Sesen Bio continues to monitor the rapidly evolving environment regarding the potential impact of the COVID-19 pandemic on our Company.

Lixte Biotechnology Comments on Outside Research Citing LB-100’s PP2A Inhibition as a Potential Therapeutic Strategy for Triple-Negative Breast Cancer

Retrieved on: 
Tuesday, July 13, 2021
Branches of biology, Oncology, Cancer treatments, Chemotherapy, Occupational safety and health, Health, Protein phosphatase 2

It was noted that LB-100 sensitizes TNBC cells to the chemotherapeutic drugs, paclitaxel and cisplatin, which are commonly used for the treatment of TNBC.

Key Points: 
  • It was noted that LB-100 sensitizes TNBC cells to the chemotherapeutic drugs, paclitaxel and cisplatin, which are commonly used for the treatment of TNBC.
  • Pimentel and his coauthors concluded that their data suggest that inhibition of PP2A activity could be a novel therapeutic approach to this notoriously unresponsive sub-type of breast cancer ( Uddin, Pimentel et al, Cell Cycle 2020 ).
  • A major driver of cancer is defects in the switches that turn the biochemical pathways in cells on and off.
  • This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at sec.gov/edgar.shtml .

Colorectal Cancer Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030 Following a 2.2% Decrease in 2021 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 9, 2021
Health, Oncology, Cancer, Clinical medicine, Medicine, Oncology, Colorectal cancer, Chemotherapy

The "Colorectal Cancer Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Colorectal Cancer Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering.
  • Colorectal Cancer Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030 provides strategists, marketers and senior management with the critical information they need to assess the global colorectal cancer drugs market as it emerges from the COVID-19 shut down.
  • The colorectal cancer drugs market consists of sale of colorectal cancer drugs.
  • The increase in number of colorectal cases will add to the overall size of the global colorectal cancer drugs market.

Active Biotech’s partner NeoTX will host KOL webinar on overcoming check point Inhibitor resistance

Retrieved on: 
Thursday, July 8, 2021
Clinical medicine, Medicine, Cancer, Oncology, Cancer immunotherapy, Immune system, Chemotherapy, Checkpoint inhibitor

Lund, July 8 2021 - Active Biotech (Nasdaq Stockholm: ACTI) today provided information that its partner in the naptumomab project, NeoTX will host a key opinion leader (KOL) webinar on overcoming checkpoint inhibitor resistance on Wednesday, July 14th at 10 am eastern time (ET)

Key Points: 
  • Lund, July 8 2021 - Active Biotech (Nasdaq Stockholm: ACTI) today provided information that its partner in the naptumomab project, NeoTX will host a key opinion leader (KOL) webinar on overcoming checkpoint inhibitor resistance on Wednesday, July 14th at 10 am eastern time (ET)
    The webinar will feature a presentation by KOL Mario Sznol, MD, Yale Cancer Center, who will discuss New Frontiers for Checkpoint Inhibitors in Immuno-Oncology.
  • NeoTX's management will also give an update on their Tumor Targeted Superantigen (TTS) platforms lead candidate, naptumomab estafenatox (naptumomab) in overcoming resistance.
  • Naptumomab is being evaluated in combination with chemotherapy, checkpoint inhibitors and CAR T. Dr. Sznol and NeoTX management will be available to answer questions following the formal presentations.
  • Since 2016, Active Biotech has a licensing agreement with NeoTX Therapeutics Ltd. for the worldwide development and commercialization of naptumomab for cancer therapy.